Sai Life Sciences Limited Set to Approve Q2 FY27 Results

Sai Life Sciences Limited is scheduled to consider its unaudited Q2 FY27 results on November 5, 2026, following Q1 FY27 consolidated revenue from operations of ₹554 crore and profit after tax of ₹73 crore. The announcement matters because it will provide the first reported update on the company’s September-quarter performance and first-half financial position.

When will Sai Life Sciences Limited announce Q2 FY27 results?

Sai Life Sciences Limited has informed the exchanges that its board meeting is scheduled for November 5, 2026, to consider and approve unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026. At the time of the announcement, the Q2 FY27 figures had not been filed.

The company has also scheduled an earnings conference call for November 6, 2026, at 11:00 AM IST. The call is intended to discuss unaudited Q2 and H1 FY27 results, allowing analysts and investors to review management’s commentary after the board-approved results are released.

Sai Life Sciences stated that its trading window was closed from October 1 to November 7, 2026, in connection with the board meeting and financial-results process. The company’s October 1 exchange intimation also referred to other corporate matters, without providing further details in the supplied disclosure.

What did Sai Life Sciences report in Q1 FY27?

Sai Life Sciences reported consolidated revenue from operations of ₹554 crore for the quarter ended June 30, 2026, compared with ₹496 crore in Q1 FY26, representing 12% year-on-year growth. Consolidated profit after tax was ₹73 crore, up 22% from the corresponding quarter a year earlier.

The company reported EBITDA of ₹148 crore in Q1 FY27, against ₹125 crore in Q1 FY26. EBITDA margin was 27%, compared with 25% a year earlier. Management attributed the reported performance to growth across its contract research organisation and contract development and manufacturing businesses, along with operating leverage and product mix.

On a sequential basis, the quarterly data supplied shows revenue declining from ₹602 crore in March 2026 to ₹554 crore in June 2026. Net profit declined from ₹104 crore to ₹73 crore over the same period. The supplied quarterly table showed operating profit margin at 18.4% in June 2026, compared with 21.8% in March 2026.

What business factors will investors assess in the Q2 release?

Sai Life Sciences operates as a contract research, development and manufacturing organisation, providing services across discovery, process development, clinical and commercial manufacturing, and technology platforms. The company is headquartered in Hyderabad and has stated that it has a global presence.

In Q1 FY27, the company said its CRO business grew 24% year on year. Management also cited 33 active commercial molecules and 14 late-phase molecules in its chemistry, manufacturing and controls pipeline. These operating disclosures provide context for investors assessing revenue momentum and the development of the company’s commercial pipeline in Q2.

The company has indicated that H2 FY27 is expected to be stronger than H1 because new capacity is coming online. A previously disclosed capacity project was the completion of Phase II of Production Block 11 at Bidar, India, which expanded capacity to 700 KL in August 2025.

How has the market positioned Sai Life Sciences before the results?

Sai Life Sciences shares closed at ₹1,559.70 on the BSE on October 30, 2026, up ₹64.75 or 4.33% for the session. This is the latest supplied market-price data before the scheduled November 5 board meeting.

The company became publicly listed through its initial public offering on the NSE and BSE in December 2024. Its Q2 disclosure is therefore relevant to public-market investors monitoring the progress of its CRO and CDMO operations, margins, capacity additions and management’s H2 FY27 outlook.

No Q2 revenue, profit, margin or guidance figures were included in the supplied material. The November 5 results and the following day’s conference call are the scheduled events that can clarify the company’s reported financial and operational performance for the September quarter.

Why do the Q2 results matter for the CRDMO business?

The Q2 release matters because it will show whether the year-on-year growth reported in Q1 continued through the first half of FY27. It will also provide updated standalone and consolidated numbers, which are important for evaluating the contribution of the company’s businesses and its reported profitability.

The June-quarter comparison showed that year-on-year revenue and EBITDA increased, while the sequential figures in the supplied data were lower than the March-quarter levels. Investors will therefore be able to compare Q2 results with both Q1 FY27 and the September 2025 quarter once the company files its financial statements.

Conclusion

Sai Life Sciences Limited is due to place its Q2 FY27 and H1 FY27 unaudited results before its board on November 5. Its latest reported quarter recorded ₹554 crore in revenue from operations, ₹148 crore in EBITDA and ₹73 crore in profit after tax, while the September-quarter financial figures remain undisclosed.

The next disclosed milestone is the November 6, 2026 earnings call, where management is scheduled to discuss the Q2 and H1 results. Investors will watch for reported revenue growth, profitability, the status of capacity additions and any update to the company’s expectation of a stronger H2 FY27.